De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Crinetics Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Crinetics Pharmaceuticals' is R. Struthers, benoemd in Dec2008, heeft een ambtstermijn van 15.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.75M, bestaande uit 10.7% salaris en 89.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.28% van de aandelen van het bedrijf, ter waarde $ 52.19M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 4.1 jaar.
Belangrijke informatie
R. Struthers
Algemeen directeur
US$5.7m
Totale compensatie
| Percentage CEO-salaris | 10.7% |
| Dienstverband CEO | 15.8yrs |
| Eigendom CEO | 1.3% |
| Management gemiddelde ambtstermijn | 3.2yrs |
| Gemiddelde ambtstermijn bestuur | 4.1yrs |
Recente managementupdates
Recent updates
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Oct 02
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Aug 12Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
Apr 24Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$259m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$6m | US$614k | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$38m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$3m | US$410k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$385k | US$350k | -US$9m |
Compensatie versus markt: De totale vergoeding ($USD 5.75M ) R. } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).
Compensatie versus inkomsten: De vergoeding van R. is gestegen terwijl het bedrijf verliesgevend is.
CEO
R. Struthers (61 yo)
15.8yrs
Tenure
US$5,747,994
Compensatie
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 15.8yrs | US$5.75m | 1.28% $ 54.3m | |
| Founder & Chief Scientific Officer | 3yrs | US$2.50m | 0.025% $ 1.0m | |
| Chief Financial Officer | 6.8yrs | US$2.51m | 0.072% $ 3.1m | |
| Chief Operating Officer | 3.1yrs | US$2.36m | 0.0051% $ 215.2k | |
| Chief Endocrinologist | 6.3yrs | US$2.16m | 0.016% $ 692.0k | |
| Chief Commercial Officer | 2.7yrs | US$1.71m | 0.0022% $ 93.6k | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| General Counsel & Corporate Secretary | 3.3yrs | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 4.4yrs | geen gegevens | geen gegevens | |
| Head of Intellectual Property | no data | geen gegevens | geen gegevens | |
| Chief Business Officer | 2.6yrs | geen gegevens | geen gegevens | |
| Chief Medical & Development Officer | 2.1yrs | US$3.61m | 0.0027% $ 113.1k |
3.2yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CRNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 15.9yrs | US$5.75m | 1.28% $ 54.3m | |
| Independent Chairman of the Board | 9yrs | US$375.31k | 0.13% $ 5.6m | |
| Independent Director | 6.7yrs | US$348.56k | 0.023% $ 985.0k | |
| Independent Director | 4.1yrs | US$339.56k | 0.0075% $ 319.0k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 2.8yrs | US$338.56k | 0.014% $ 584.4k | |
| Independent Director | 6.7yrs | US$338.56k | 0.0075% $ 319.0k | |
| Independent Director | 5.3yrs | US$342.31k | 0.0075% $ 319.0k | |
| Independent Director | 2.6yrs | US$330.06k | 0.0075% $ 319.0k | |
| Member of Scientific Advisory Board | 2.5yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 2.5yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 2.5yrs | geen gegevens | geen gegevens |
4.1yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CRNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).